Financial results for the period ended Jun 30, 2026
As filed · Aurobindo Pharma Limited has submitted to the Exchange, the financial results for the period ended Jun 30, 2026.
EarningsMajormateriality 77 out of 100
What happened
FactAurobindo Pharma Ltd. announced the approval of its standalone and consolidated unaudited financial results for the first quarter ended June 30, 2026, during a board meeting on August 5, 2026. The board also approved a proposal to file a Scheme of Amalgamation for the merger of its wholly owned subsidiaries, Eugia Steriles Private Limited and Eugia SEZ Private Limited, with Eugia Pharma Specialities Limited. The meeting commenced at 4:00 p.m. and concluded at 6:30 p.m.
Why it matters
CapitSignal interpretationReported results are the point at which prior management commitments become checkable against audited or reviewed numbers.
Watch next
Fact- Margin trend against the prior period
- Cash from operations against reported profit
- Whether prior guidance is reaffirmed
- This approval has been received from Eugia Unit-I and is expected to be launched in Q1FY27. (management committed by Q1 FY27)
Evidence
How CapitSignal classified this
- Reasoning:
- RESULTS base 68; +4 corroborating keywords; +5 quantified amount; matched on subject
- Matched on:
- the filing's own subject line
- Confidence in the event type:
- 90%